Truist Securities Reiterates Buy Rating on Boston Scientific (BSX) Following Bolt Medical Acquisition
Tweet Send to a Friend
Truist Securities analyst Richard Newitter reiterated a Buy rating and $110.00 price target on Boston Scientific (NYSE: BSX).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
